<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2018-3.5.4</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-703</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ВНУТРЕННИЕ БОЛЕЗНИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INTERNAL DISEASES</subject></subj-group></article-categories><title-group><article-title>ВЛИЯНИЕ СТАТИНА ПРИ ДОБАВЛЕНИИ К АНТИГИПЕРТЕНЗИВНОЙ ТЕРАПИИ НА ПОКАЗАТЕЛИ СОСУДИСТОЙ ЖЁСТКОСТИ У БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ ВЫСОКОГО СЕРДЕЧНО-СОСУДИСТОГО РИСКА</article-title><trans-title-group xml:lang="en"><trans-title>THE EFFECT OF STATIN ADDED TO ANTIHYPERTENSIVE THERAPY ON ARTERIAL STIFFNESS IN HYPERTENSIVE PATIENTS AT HIGH CARDIOVASCULAR RISK</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0155-676X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Федоришина</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fedorishina</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>664049, г. Иркутск, Юбилейный, 100.</p><p>кандидат медицинских наук, доцент кафедры кардиологии и функциональной диагностики.</p></bio><bio xml:lang="en"><p>664049, Irkutsk, Yubileyniy, 100.</p><p>Candidate of Medical Sciences, Associate Professor at the Department of Cardiology and Functional Diagnostics.</p></bio><email xlink:type="simple">olff@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6516-3180</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Протасов</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Protasov</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>664049, г. Иркутск, Юбилейный, 100.</p><p>доктор медицинских наук, профессор, заведующий кафедрой кардиологии и функциональной диагностики.</p><p> </p><p> </p></bio><bio xml:lang="en"><p>664049, Irkutsk, Yubileyniy, 100.</p><p>Doctor of Medical Sciences, Professor, Head of the Department of Cardiology and Functional Diagnostics.</p></bio><email xlink:type="simple">protassov_k@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9588-1709</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Торунова</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Torunova</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>664049, г. Иркутск, Юбилейный, 100.</p><p>ассистент кафедры терапии.</p></bio><bio xml:lang="en"><p>664049, Irkutsk, Yubileyniy, 100.</p><p>Teaching Assistant at the Department of General Medicine.</p></bio><email xlink:type="simple">torunova.am@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Иркутская государственная медицинская академия последипломного образования – филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России.</institution></aff><aff xml:lang="en"><institution>Irkutsk State Medical Academy of Postgraduate Education – Branch Campus of the Russian Medical Academy of Continuing Professional Education.</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>28</day><month>09</month><year>2018</year></pub-date><volume>3</volume><issue>5</issue><fpage>27</fpage><lpage>32</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Федоришина О.В., Протасов К.В., Торунова А.М., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Федоришина О.В., Протасов К.В., Торунова А.М.</copyright-holder><copyright-holder xml:lang="en">Fedorishina O.V., Protasov K.V., Torunova A.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/703">https://www.actabiomedica.ru/jour/article/view/703</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Повышенная жёсткость сосудов является независимым фактором риска сердечно-сосудистых событий, в том числе при артериальной гипертензии. Положительное влияние на данный показатель в разной степени оказывают все основные группы антигипертензивных препаратов. Данные по влиянию статинов на артериальную жёсткость неоднозначны.</p></sec><sec><title>Цель исследования</title><p>Цель исследования: изучить динамику показателей сосудистой жёсткости у больных артериальной гипертензией высокого или очень высокого сердечно-сосудистого риска при добавлении розувастатина к комбинированной двухкомпонентной антигипертензивной терапии амлодипином и лизиноприлом.</p></sec><sec><title>Методы</title><p>Методы. 60 пациентов были рандомизированно распределены на две группы: первая группа получала фиксированную комбинацию амлодипин/лизиноприл, вторая дополнительно к этому режиму терапии принимала розувастатин. В изучаемых группах оценивали и сравнивали динамику офисного и среднесуточного артериального давления, центрального давления в аорте, скорости распространения пульсовой волны на каротидно-феморальном и каротидно-радиальном сегментах.</p></sec><sec><title>Результаты</title><p>Результаты. К окончанию 24-недельного периода лечения отмечено статистически значимое снижение офисного и среднесуточного артериального давления в обеих группах с большей степенью уменьшения офисного диастолического артериального давления в группе добавления статина. Центральное артериальное давление в аорте также снизилось в обеих группах в равной степени. Индекс аугментации статистически значимо уменьшился в обеих группах, в большей степени – во второй группе (–4,8 % и –9,4 % соответственно; р = 0,036). Каротидно-феморальная скорость распространения пульсовой волны снизилась в одинаковой степени в обеих группах, а каротидно-радиальная – только во второй (с 9,5 ± 1,8 до 8,8 ± 1,1 м/с; р = 0,026).</p></sec><sec><title>Заключение</title><p>Заключение. Добавление розувастатина к фиксированной комбинации амлодипин/лизиноприл в лечении больных артериальной гипертензией высокого и очень высокого сердечно-сосудистого риска сопровождалось более выраженным снижением офисного диастолического давления, индекса аугментации и статистически значимо уменьшало каротидно-феморальную и каротидно-радиальную скорость распространения пульсовой волны.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Little is known about the effect of statins addition to standard antihypertensive therapy on blood pressure level and vascular stiffness in high-risk hypertensive patients.</p><p>The aim of the study was to assess the dynamics of vascular stiffness in hypertensive patients of high or very high cardiovascular risk under the influence of rosuvastatin addition to combined two-component amlodipine and lisinopril antihypertensive therapy.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. We investigated 60 hypertensive patients who were randomized into two groups: the 1st group received a fixed amlodipine/lisinopril combination, the 2nd one followed the same regimen of therapy with addition of 20 mg rosuvastatin. Mean office and ambulatory blood pressure as well as central aortic blood pressure and pulse wave velocity were evaluated in both groups before and after 24-week follow-up period.</p></sec><sec><title>Results</title><p>Results. At end of follow-up period the office and average daily blood pressure significantly decreased in both groups, with more prominent office diastolic blood pressure decline in the 2nd one. The central aortic blood pressure equally decreased in both groups. The augmentation index significantly reduced in both groups, mostly in the 2nd one. The carotid-femoral pulse wave velocity declined in both groups to the same extent. The carotid-radial pulse wave velocity decreased statistically only in the second group.</p></sec><sec><title>Conclusions</title><p>Conclusions. Addition of rosuvastatin to a fixed amlodipine/lisinopril combination in high/very high cardiovascular risk hypertensive patients was accompanied by more pronounced decline of diastolic blood pressure and augmentation index, as well as significantly reduction of pulse wave velocity.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>розувастатин</kwd><kwd>лизиноприл</kwd><kwd>амлодипин</kwd><kwd>жёсткость сосудов</kwd><kwd>скорость распространения пульсовой волны</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hypertension</kwd><kwd>rosuvastatin calcium</kwd><kwd>lisinopril</kwd><kwd>amlodipine</kwd><kwd>vascular stiffness</kwd><kwd>pulse wave velocity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Агеев Ф.Т., Бланкова З.Н., Самсонова Н.С. Эффект перевода пациентов с артериальной гипертензией и высоким сердечно-сосудистым риском с обычной гипотензивной терапии на терапию тройной фиксированной комбинацией с розувастатином: исследование «АлРОЗА» // Кардиология. – 2018. – № S3. – С. 46–54. DOI: 10.18087/cardio.2470</mixed-citation><mixed-citation xml:lang="en">Ageev FT, Blankova ZN, Samsonova NS. (2018). The effect of changing conventional antihypertensive therapy for a triple fixed combination therapy with rosuvastatin in hypertensive patients with high cardiac risk [Effekt perevoda patsientov s arterial’noy gipertenziey i vysokim serdechno-sosudistym riskom s obychnoy gipotenzivnoy terapii na terapiyu troynoy fiksirovannoy kombinatsiey s rozuvastatinom: issledovanie «AlROZA»]. Kardiologiya, (S3), 46-54. DOI: 10.18087/cardio.2470</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Бланкова З.Н., Асланян Н.С. Влияние комбинированной терапии на состояние сосудистой стенки у больных высокого сердечно-сосудистого риска // Системные гипертензии. – 2017. – Т. 14, № 2. – С. 51–55. DOI: 10.26442/2075-082X_14.2.51-55</mixed-citation><mixed-citation xml:lang="en">Blankova ZN, Aslanyan NS. (2017). The effect of combined therapy on the vessel wall in patients with high cardiac risk [Vliyanie kombinirovannoy terapii na sostoyanie sosudistoy stenki u bol’nykh vysokogo serdechno-sosudistogo riska]. Sistemnye gipertenzii, 14 (2), 51-55. DOI: 10.26442/2075-082X_14.2.51-55</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О., Палаткина Л., Зятенкова Е. Плейотропные эффекты статинов. Влияние на жёсткость сосудов // Врач. – 2012. – № 9. – С. 5–8.</mixed-citation><mixed-citation xml:lang="en">Drapkina O, Palatkina L, Zyatenkova E. (2012). Pleiotropic effects of statins. Effect on vascular stiffness [Pleyotropnye effekty statinov. Vliyanie na zhestkost’ sosudov]. Vrach, (9), 5-8.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Дроздецкий С.И., Кучин К.В. Возможности коррекции сосудистой жёсткости с использованием двух режимов терапии // Международный журнал сердца и сосудистых заболеваний. – 2016. – Т. 4, № 9. – С. 25–36. DOI: 10.15829/2311-1623-4-9</mixed-citation><mixed-citation xml:lang="en">Drozdetskiy SI, Kuchin KV. (2016). Possibilities of using two treatment regimen for vascular stiffness correction [Vozmozhnosti korrektsii sosudistoy zhestkosti s ispol’zovaniem dvukh rezhimov terapii]. Mezhdunarodnyy zhurnal serdtsa i sosudistykh zabolevaniy, 4 (9), 25-36.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Кароли Н.А., Ребров А.П., Рощина А.А. Сергеева В.А., Архангельская Е.Е. Эффективность и безопасность амлодипина малеата у больных хронической обструктивной болезнью легких и бронхиальной астмой с сопутствующей артериальной гипертонией // Рациональная фармакотерапия в кардиологии. – 2010. – Т. 6, № 2. – С. 173-178. DOI: 10.20996/1819-6446-2010-6-2-173-178</mixed-citation><mixed-citation xml:lang="en">Karoli NA, Rebrov AP, Roshchina AA, Sergeeva VA, Arkhangelskaya EE. (2010). Efficacy and safety of amlodipine maleate in patients with chronic obstructive pulmonary disease and bronchial asthma with concomitant arterial hypertension [Effektivnost’ i bezopasnost’ amlodipina maleata u bol’nykh khronicheskoy obstruktivnoy bolezn’yu legkikh i bronkhial’noy astmoy s soputstvuyushchey arterial’noy gipertoniey]. Ratsional’naya farmakoterapiya v kardiologii, 6 (2), 173-178. DOI: 10.20996/1819-6446-2010-6-2-173-178</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Карпов Ю.А. Исследование ТРИУМВИРАТ: снижение риска развития сердечно-сосудистых осложнений у больных АГ с помощью трехкомпонентной комбинации антигипертензивных и липидснижающих препаратов // Кардиология. – 2015. – Т. 55, № 9. – С. 10–15..</mixed-citation><mixed-citation xml:lang="en">Karpov YuA. (2015). TRIUMVIRATE study: reducing cardiac risk in hypertensive patients using triple combination antihypertensive and lipid-lowering drugs [Issledovanie TRIUMVIRAT: snizhenie riska razvitiya serdechno-sosudistykh oslozhneniy u bol’nykh AG s pomoshch’yu trekhkomponentnoy kombinatsii antigipertenzivnykh i lipidsnizhayushchikh preparatov]. Kardiologiya, 55 (9), 10-15.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации. Диагностика и лечение артериальной гипертонии // Кардиологический вестник. – 2015. – Т. 10, № 1. – С. 3–30. Clinical guidelines. Diagnostics and treatment of arterial hypertension. (2015).</mixed-citation><mixed-citation xml:lang="en">Klinicheskie rekomendatsii. Diagnostika i lechenie arterial’noy gipertonii. Kardiologicheskiy vestnik, 10 (1), 3-30.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Кобалава Ж.Д., Котовская Ю.В., Троицкая Е.А. Комбинация блокатора ренинангиотензиновой системы и дигидропиридинового антагониста кальция в лечении артериальной гипертонии // Русский медицинский журнал. – 2010. – № 3. – С. 123–126.</mixed-citation><mixed-citation xml:lang="en">Kobalava ZhD, Kotovskaya YuV, Troitskaya EA. (2010). Combination of the rennin-angiotensin system blocker and dihydropyridine calcium antagonist in the treatment of arterial hypertension [Kombinatsiya blokatora reninan-giotenzinovoy sistemy i digidropiridinovogo antagonista kal’tsiya v lechenii arteri-al’noy gipertonii]. Russkiy meditsinskiy zhurnal, (3), 123-126.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Протасов К.В., Синкевич Д.А., Решина И.В., Жижко Н.В., Логовикова С.И., Голубева Л.В. Сосудистые эффекты фиксированной комбинации периндоприла аргинина и индапамида у больных артериальной гипертензией // Кардиология. – 2012. – № 9. – С. 8–14.</mixed-citation><mixed-citation xml:lang="en">Protasov KV, Sinkevich DA, Reshina IV, Zhizhko NV, Logovikova SI, Golubeva LV. (2012). Vascular effects of the perindopril arginine and indapamide fixed combination in patients with arterial hypertension [Sosudistye effekty fiksirovannoy kombinatsii perindoprila arginina i indapamida u bol’nykh arterial’noy gipertenziey]. Kardiologiya, (9), 8-14.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Asmar R. (2001). Effect of antihypertensive agents on arterial stiffness as evaluated by pulse wave velocity: clinical implications. Am J Cardiovasc Drugs, 1 (5), 387-397.</mixed-citation><mixed-citation xml:lang="en">Asmar R. (2001). Effect of antihypertensive agents on arterial stiffness as evaluated by pulse wave velocity: clinical implications. Am J Cardiovasc Drugs, 1 (5), 387-397.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT Investigators. (2005). Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet, 366 (9489), 895-906. DOI: 10.1016/S0140-6736(05)67185-1</mixed-citation><mixed-citation xml:lang="en">Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT Investigators. (2005). Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet, 366 (9489), 895-906. DOI: 10.1016/S0140-6736(05)67185-1</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">D’elia L, La Fata E, Iannuzzi A, Rubba PO. (2018). Effect of statin therapy on pulse wave velocity: A meta-analysis of randomized controlled trials. Clin Exp Hypertens, 8, 1-8. DOI: 10.1080/10641963.2017.1411498</mixed-citation><mixed-citation xml:lang="en">D’elia L, La Fata E, Iannuzzi A, Rubba PO. (2018). Effect of statin therapy on pulse wave velocity: A meta-analysis of randomized controlled trials. Clin Exp Hypertens, 8, 1-8. DOI: 10.1080/10641963.2017.1411498</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H; European Network for Non-invasive Investigation of Large Arteries. (2005). Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J, 27 (21), 2588-2605. DOI: 10.1093/eurheartj/ehl254</mixed-citation><mixed-citation xml:lang="en">Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H; European Network for Non-invasive Investigation of Large Arteries. (2005). Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J, 27 (21), 2588-2605. DOI: 10.1093/eurheartj/ehl254</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Laurent S, Katsahian S, Fassot C, Tropeano AI, Gautier I, Laloux B, Boutouyrie P. (2003) Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke, 34 (5), 1203-1206. DOI: 10.1161/01. STR.0000065428.03209.64</mixed-citation><mixed-citation xml:lang="en">Laurent S, Katsahian S, Fassot C, Tropeano AI, Gautier I, Laloux B, Boutouyrie P. (2003) Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke, 34 (5), 1203-1206. DOI: 10.1161/01. STR.0000065428.03209.64</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Muiesan ML, Salvetti M, Monteduro C, Rizzoni D, Zulli R, Corbellini C, Brun C, Agabiti-Rosei E. (1999). Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension, 33 (1 Pt 2), 575-580.</mixed-citation><mixed-citation xml:lang="en">Muiesan ML, Salvetti M, Monteduro C, Rizzoni D, Zulli R, Corbellini C, Brun C, Agabiti-Rosei E. (1999). Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension, 33 (1 Pt 2), 575-580.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Nürnberger J, Keflioglu-Scheiber A, Opazo Saez AM, Wenzel RR, Philipp T, Schäfers RF. (2002). Augmentation index is associated with cardiovascular risk. J Hypertens, 20 (12), 2407-2414. DOI: 10.1097/01.hjh.0000045501.82010.fa</mixed-citation><mixed-citation xml:lang="en">Nürnberger J, Keflioglu-Scheiber A, Opazo Saez AM, Wenzel RR, Philipp T, Schäfers RF. (2002). Augmentation index is associated with cardiovascular risk. J Hypertens, 20 (12), 2407-2414. DOI: 10.1097/01.hjh.0000045501.82010.fa</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Schaefer CA, Blatzheim AK, Passon SG, Pausewang KS, Schahab N, Nickenig G, Skowasch D, Schueler R, Hammerstingl C, Pingel S. (2017). Modulation of carotid strain by statin therapy in atherosclerosis patients. Vasa, 46 (2), 108-115. DOI: 10.1024/0301-1526/a000596</mixed-citation><mixed-citation xml:lang="en">Schaefer CA, Blatzheim AK, Passon SG, Pausewang KS, Schahab N, Nickenig G, Skowasch D, Schueler R, Hammerstingl C, Pingel S. (2017). Modulation of carotid strain by statin therapy in atherosclerosis patients. Vasa, 46 (2), 108-115. DOI: 10.1024/0301-1526/a000596</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Strazzullo P, Kerry SM, Barbato A, Versiero M, D’Elia L, Cappuccio FP. (2007). Do statins reduce blood pressure: a meta-analysis of randomized, controlled trials. Hypertension, 49 (4), 792-798. DOI: 10.1161/01.HYP.0000259737.43916.42</mixed-citation><mixed-citation xml:lang="en">Strazzullo P, Kerry SM, Barbato A, Versiero M, D’Elia L, Cappuccio FP. (2007). Do statins reduce blood pressure: a meta-analysis of randomized, controlled trials. Hypertension, 49 (4), 792-798. DOI: 10.1161/01.HYP.0000259737.43916.42</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O’Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. (2006). Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation, 113 (9), 1213-1225. DOI: 10.1161/CIRCULATIONAHA.105.595496</mixed-citation><mixed-citation xml:lang="en">Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O’Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. (2006). Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation, 113 (9), 1213-1225. DOI: 10.1161/CIRCULATIONAHA.105.595496</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. (2006). Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation, 113 (5), 664-670. DOI: 0.1161/CIRCULATIONAHA.105.579342</mixed-citation><mixed-citation xml:lang="en">Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. (2006). Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation, 113 (5), 664-670. DOI: 0.1161/CIRCULATIONAHA.105.579342</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
